Agios Pharmaceuticals Financials
| 8AP Stock | EUR 52.50 1.50 2.94% |
Agios |
Understanding current and past Agios Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Agios Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Agios Pharmaceuticals' assets may result in an increase in income on the income statement.
Agios Pharmaceuticals Stock Summary
Agios Pharmaceuticals competes with Superior Plus, NMI Holdings, Origin Agritech, SIVERS SEMICONDUCTORS, and Talanx AG. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. AGIOS PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 482 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US00847X1046 |
| Business Address | 88 Sidney Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.agios.com |
| Phone | 617 649 8600 |
| Currency | EUR - Euro |
You should never invest in Agios Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Agios Stock, because this is throwing your money away. Analyzing the key information contained in Agios Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Agios Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Agios Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Agios Pharmaceuticals reports annually and quarterly.Agios Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Agios Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Agios Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Agios Pharmaceuticals competition to find correlations between indicators driving Agios Pharmaceuticals's intrinsic value. More Info.Agios Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Agios Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Agios Pharmaceuticals Systematic Risk
Agios Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Agios Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Agios Pharmaceuticals correlated with the market. If Beta is less than 0 Agios Pharmaceuticals generally moves in the opposite direction as compared to the market. If Agios Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Agios Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Agios Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Agios Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Agios Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Agios Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Agios Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Agios Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Agios Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Agios Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.83 | |||
| Information Ratio | 0.0976 | |||
| Maximum Drawdown | 15.54 | |||
| Value At Risk | (3.81) | |||
| Potential Upside | 6.8 |
Complementary Tools for Agios Stock analysis
When running Agios Pharmaceuticals' price analysis, check to measure Agios Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharmaceuticals is operating at the current time. Most of Agios Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Agios Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharmaceuticals' price. Additionally, you may evaluate how the addition of Agios Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |